BioMarin Pharmaceutical I... (BMRN)

It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all...

The second half of 2025 is fast approaching, and the stock market is promising a crazy ride with some exciting news hitting the headlines.

Investors need to pay close attention to BioMarin Pharmaceutical stock based on the movements in the options market lately.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inozy...

BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

BMRN reports encouraging first-quarter results. The company reiterates its financial guidance for 2025.

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare ...